Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response

Leuk Lymphoma. 2019 Mar;60(3):852-855. doi: 10.1080/10428194.2018.1509319. Epub 2018 Sep 19.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Amyloidosis / diagnosis*
  • Amyloidosis / etiology*
  • Hematologic Neoplasms / etiology*
  • Humans
  • Janus Kinase 2 / antagonists & inhibitors
  • Janus Kinase 2 / genetics
  • Janus Kinase Inhibitors / adverse effects
  • Janus Kinase Inhibitors / therapeutic use
  • Kidney Diseases / diagnosis*
  • Kidney Diseases / etiology*
  • Male
  • Middle Aged
  • Primary Myelofibrosis / complications*
  • Primary Myelofibrosis / drug therapy
  • Primary Myelofibrosis / genetics
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use
  • Tomography, X-Ray Computed

Substances

  • INCB018424
  • Janus Kinase Inhibitors
  • Pyrazoles
  • Janus Kinase 2